These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22161573)

  • 41. Solid-state protein formulations.
    Angkawinitwong U; Sharma G; Khaw PT; Brocchini S; Williams GR
    Ther Deliv; 2015 Jan; 6(1):59-82. PubMed ID: 25565441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring of subvisible particles in therapeutic proteins.
    Singh SK; Toler MR
    Methods Mol Biol; 2012; 899():379-401. PubMed ID: 22735966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of the analytical characterization of nanostructured drug delivery systems: towards green and sustainable pharmaceuticals: a review.
    Domingo C; Saurina J
    Anal Chim Acta; 2012 Sep; 744():8-22. PubMed ID: 22935368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.
    Leurs U; Mistarz UH; Rand KD
    Eur J Pharm Biopharm; 2015 Jun; 93():95-109. PubMed ID: 25791210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Particle sizing measurements in pharmaceutical applications: comparison of in-process methods versus off-line methods.
    Silva AF; Burggraeve A; Denon Q; Van der Meeren P; Sandler N; Van Den Kerkhof T; Hellings M; Vervaet C; Remon JP; Lopes JA; De Beer T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1006-18. PubMed ID: 23583493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What can we learn from atomic force microscopy adhesion measurements with single drug particles?
    Roberts CJ
    Eur J Pharm Sci; 2005 Feb; 24(2-3):153-7. PubMed ID: 15661486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simple method for the detection of insoluble aggregates in protein formulations.
    Li B; Flores J; Corvari V
    J Pharm Sci; 2007 Jul; 96(7):1840-3. PubMed ID: 17299781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
    Huang CT; Sharma D; Oma P; Krishnamurthy R
    J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.
    Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size.
    Sinha B; Müller RH; Möschwitzer JP
    Int J Pharm; 2013 Aug; 453(1):126-41. PubMed ID: 23333709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Application of computer image analysis for characterization of pellets].
    Balogh E; Kállai N; Dredán J; Lengyel M; Klebovich I; Antal I
    Acta Pharm Hung; 2007; 77(2):123-31. PubMed ID: 17933272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein aggregation: pathways, induction factors and analysis.
    Mahler HC; Friess W; Grauschopf U; Kiese S
    J Pharm Sci; 2009 Sep; 98(9):2909-34. PubMed ID: 18823031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells.
    Roesch A; Zölls S; Stadler D; Helbig C; Wuchner K; Kersten G; Hawe A; Jiskoot W; Menzen T
    J Pharm Sci; 2022 Apr; 111(4):933-950. PubMed ID: 34919969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High throughput screening of protein formulation stability: practical considerations.
    Capelle MA; Gurny R; Arvinte T
    Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of operating and formulation variables on the morphology of spray-dried protein particles.
    Maa YF; Costantino HR; Nguyen PA; Hsu CC
    Pharm Dev Technol; 1997 Aug; 2(3):213-23. PubMed ID: 9552449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanosizing--oral formulation development and biopharmaceutical evaluation.
    Kesisoglou F; Panmai S; Wu Y
    Adv Drug Deliv Rev; 2007 Jul; 59(7):631-44. PubMed ID: 17601629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.